Sorry, you need to enable JavaScript to visit this website.

Metabolic and Cardiovascular Disorders Development Pipeline

Metabolic and Heart Disease Drug Pipeline and Clinical Trials

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with metabolic diseases and at cardiovascular risk. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.


Internal Medicine Pipeline as of May 3, 2022
  • 00Phase 1
  • 00Phase 2
  • 00Phase 3
  • 00Registration
  • 00Total

Internal Medicine Pipeline & Trials